18F-FDOPA PET/CT在嗜铬细胞瘤与正常肾上腺中的摄取对比
该回顾性研究分析了45例组织学确诊嗜铬细胞瘤患者和245例对照,旨在确定正常肾上腺18F-FDOPA摄取的SUVmax参考值及嗜铬细胞瘤的最佳诊断阈值。结果显示,患侧肾上腺SUVmax截断值4.1时灵敏度93%、特异度85%,而患侧与正常肾上腺SUVmax差值截断值1.0时灵敏度93%、特异度96%,两者联合AUC达0.995。
要点
- 正常肾上腺18F-FDOPA摄取SUVmax中位数为2.9(范围1.1-6.6)。
- 嗜铬细胞瘤SUVmax中位数为12(范围2.6-50),显著高于对照组(p<0.001)。
- 患侧与正常肾上腺SUVmax差值≥1.0时诊断准确性更高(AUC=0.992)。
核心结论
- 18F-FDOPA PET/CT可区分嗜铬细胞瘤与正常肾上腺,联合患侧SUVmax及患侧与正常肾上腺SUVmax差值时诊断准确性最高。
研究设计与样本
- 对照组为因其他指征行18F-FDOPA PET/CT且无嗜铬细胞瘤遗传易感性的患者。
- 共纳入45例患者中的47个组织学确诊嗜铬细胞瘤及245例疾病对照。
- 在EARL重建图像上测定肾上腺感兴趣区SUVmax,采用ROC分析及二元逻辑回归分析组合参数。
主要发现
- 对照组左、右肾上腺SUVmax无统计学差异,且双侧摄取显著相关(r=0.865,p<0.001)。
- 嗜铬细胞瘤组肾上腺SUVmax中位数(范围)为12(2.6-50),对照组为2.9(1.1-6.6),组间差异显著(p<0.001)。
- 患侧肾上腺SUVmax截断值4.1时,灵敏度93%、特异度85%(AUC=0.951)。
- 患侧与正常肾上腺SUVmax差值截断值1.0时,灵敏度93%、特异度96%(AUC=0.992)。
- 联合患侧SUVmax与患侧-正常肾上腺SUVmax差值两个变量,AUC提高至0.995。
关键数值与推荐
- 正常肾上腺18F-FDOPA摄取SUVmax参考:中位数2.9,范围1.1-6.6(对照组245例)。
- 嗜铬细胞瘤18F-FDOPA摄取SUVmax:中位数12,范围2.6-50(47个病灶)。
- 患侧肾上腺SUVmax截断值4.1:灵敏度93%,特异度85%,AUC=0.951。
- 患侧与正常肾上腺SUVmax差值截断值1.0:灵敏度93%,特异度96%,AUC=0.992。
- 联合患侧SUVmax与差值变量:AUC=0.995。
临床怎么用
- 临床可参考正常肾上腺18F-FDOPA SUVmax中位数2.9及范围1.1-6.6判读图像。
- 定位嗜铬细胞瘤时,可考虑患侧肾上腺SUVmax截断值4.1或患侧与正常肾上腺SUVmax差值截断值1.0。
- 联合患侧SUVmax与患侧-正常肾上腺SUVmax差值可提高诊断准确性(AUC=0.995)。
局限性
- 本研究为单中心回顾性分析。
- 对照组为因其他指征行18F-FDOPA PET/CT且无嗜铬细胞瘤遗传易感性者,非健康人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: 18F-FDOPA PET/CT accurately localizes pheochromocytoma in patients with an established biochemical diagnosis. However, cut-off 18F-FDOPA levels of standardized uptake values (SUVmax) for both normal adrenal glands and pheochromocytoma are lacking. OBJECTIVE: Objectives of this study were to determine (1) reference maximum standardized uptake values (SUVmax) for normal adrenal 18F-DOPA tracer uptake and (2) the optimal diagnostic approach for pheochromocytoma localization by using 18F-DOPA SUVmax across a series of cut-off points: the affected adrenal gland (inter-individual analysis), the difference in SUVmax between the affected adrenal gland and the contralateral normal adrenal gland (intra-individual analysis), or a combination of these two. PATIENTS AND METHODS: All patients with histologically confirmed pheochromocytoma diagnosed at our center between November 2009 and December 2017 were retrospectively analysed. Only those patients who underwent an 18F-FDOPA PET/CT-scan for localization purposes before adrenalectomy were included for further analysis. The control group consisted of patients who underwent 18F-FDOPA PET/CT for other indications and who had no genetic susceptibility for developing a pheochromocytoma. SUVmax of the volume of interest surrounding the adrenal glands was determined on EARL reconstructed images. Receiver operating characteristic (ROC) analysis was performed for adrenal gland SUVmax and intra-individual difference in SUVmax between affected and normal adrenal gland. In addition, binary logistic regression was performed for ROC analysis of the combined parameters. RESULTS: In total, 47 histologically confirmed pheochromocytomas were diagnosed in 45 patients, and 245 disease control patients were identified. In the control group, no statistical differences between the SUVmax of left and right adrenal glands were observed, and uptake values in both adrenal glands correlated significantly with each other (r = 0.865, p < 0.001). Median (range) adrenal gland SUVmax in pheochromocytomas and in the control group was 12 (2.6-50) and 2.9 (1.1-6.6), respectively (p < 0.001). ROC analysis revealed 93% sensitivity and 85% specificity at an SUVmax cut-off value of 4.1 (area under the curve (AUC) = 0.951), and 93% sensitivity and 96% specificity at an intra-individual SUVmax difference between the affected and normal adrenal gland of 1.0 (AUC = 0.992). The combination of both variables increased the AUC to 0.995. CONCLUSIONS: 18F-FDOPA PET/CT distinguishes pheochromocytoma from normal adrenal glands with the highest diagnostic accuracy when combining the SUVmax of the affected adrenal gland with the difference in SUVmax between affected and normal adrenal gland.
引用
- Noordzij W, Glaudemans AWJM, Schaafsma M, et al. Adrenal tracer uptake by 18F-FDOPA PET/CT in patients with pheochromocytoma and controls. Eur J Nucl Med Mol Imaging. 2019. PMID: 31011769. doi:10.1007/s00259-019-04332-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。